Literature DB >> 20364335

Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.

Yaxi Ma1, Baizhou Li.   

Abstract

To investigate the significance of PRL-3 expression in progression and metastasis of squamous cell carcinoma of the cervix (SCC). PRL-3 expression was detected by immunohistochemistry in 22 normal cervical epithelia, 30 moderate-severe dysplasia (CIN II-III) and 90 SCC cases. A total of 28 patients with SCC had lymph node metastasis, and PRL-3 expression of metastatic lymph node was detected. The association between PRL-3 expression and various clinical pathological variables in 90 patients with SCC was analyzed. Expression of PRL-3 in SCC was higher than that in normal and CINII-III, as well as higher in CINII-III than in normal (P<0.05 in all instances). PRL-3 expression was significantly different between different tumor sizes, lymph-vascular space invasion status and lymph node metastasis status (P<0.05 in all instances). PRL-3 expression in lymph node metastasis was significantly higher than that in primary SCC (P=0.049). In lymph node metastasis, the frequency of staining in cytoplasm predominantly was higher than that in matched primary cancers (P=0.001). PRL-3 may be involved in carcinogenesis of cervix and lymph node metastases of SCC and serves as an unfavorable prognostic factor in patients with SCC. PRL-3 localization in plasma may be related with cancer progress and metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20364335     DOI: 10.1007/s12032-010-9514-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.

Authors:  L Wang; L Peng; B Dong; L Kong; L Meng; L Yan; Y Xie; C Shou
Journal:  Ann Oncol       Date:  2006-07-27       Impact factor: 32.976

2.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

3.  High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.

Authors:  U A Miskad; S Semba; H Kato; Y Matsukawa; Y Kodama; E Mizuuchi; N Maeda; K Yanagihara; H Yokozaki
Journal:  Virchows Arch       Date:  2007-01-18       Impact factor: 4.064

4.  Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay.

Authors:  Shin Wha Lee; Yong-Man Kim; Moon-Bo Kim; Dae-Yeon Kim; Jong-Hyeok Kim; Joo-Hyun Nam; Young-Tak Kim
Journal:  Tohoku J Exp Med       Date:  2009-12       Impact factor: 1.848

5.  PRL-3 expression in metastatic cancers.

Authors:  Alberto Bardelli; Saurabh Saha; Jason A Sager; Kathy E Romans; Baozhong Xin; Sanford D Markowitz; Christoph Lengauer; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

6.  Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.

Authors:  Upik Anderiani Miskad; Shuho Semba; Hirotaka Kato; Hiroshi Yokozaki
Journal:  Pathobiology       Date:  2004       Impact factor: 4.342

7.  Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.

Authors:  Yu-Qiong Liu; Hui-Xiang Li; Xi Lou; Jun-Yi Lei
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

8.  Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.

Authors:  Zhao Wang; Shi-Rong Cai; Yu-Long He; Wen-Hua Zhan; Chang-Hua Zhang; Hui Wu; Jian-Jun Peng; Jian-Bo Xu; Xin-Hua Zhang; Liang Wang; Wu Song
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-09       Impact factor: 4.553

Review 9.  Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.

Authors:  H W Hirte; J E Strychowsky; T Oliver; M Fung-Kee-Fung; L Elit; A M Oza
Journal:  Int J Gynecol Cancer       Date:  2007-06-01       Impact factor: 3.437

10.  Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.

Authors:  Xiaopeng Wu; Hu Zeng; Xianming Zhang; Ying Zhao; Haibo Sha; Xiaomei Ge; Minyue Zhang; Xiang Gao; Qiang Xu
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

View more
  10 in total

1.  Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.

Authors:  Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

Review 2.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

3.  Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.

Authors:  Sheng-Yi Lin; Yue-Xun Lee; Sung-Liang Yu; Gee-Chen Chang; Jeremy J W Chen
Journal:  Oncotarget       Date:  2016-04-19

4.  PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression.

Authors:  Hua Xie; Hao Wang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

5.  A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.

Authors:  Chuanyuan Liu; Wu Zhong; Laiyang Xia; Chuanfa Fang; Hongquan Liu; Xiaochun Liu
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

6.  Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.

Authors:  Abudureheman Mayinuer; Mahmut Yasen; Kaoru Mogushi; Gulanbar Obulhasim; Maimaiti Xieraili; Arihiro Aihara; Shinji Tanaka; Hiroshi Mizushima; Hiroshi Tanaka; Shigeki Arii
Journal:  Ann Surg Oncol       Date:  2012-10-13       Impact factor: 5.344

7.  Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene.

Authors:  Krystle T Pagarigan; Bryce W Bunn; Jake Goodchild; Travis K Rahe; Julie F Weis; Leslie J Saucedo
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

8.  Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.

Authors:  Shuang Qu; Bin Liu; Xiaoling Guo; Hongshun Shi; Meifeng Zhou; Li Li; Shulan Yang; Xiuzhen Tong; Haihe Wang
Journal:  Cancer       Date:  2014-04-15       Impact factor: 6.860

9.  Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.

Authors:  Esten N Vandsemb; Helena Bertilsson; Pegah Abdollahi; Øystein Størkersen; Thea Kristin Våtsveen; Morten Beck Rye; Torstein Baade Rø; Magne Børset; Tobias S Slørdahl
Journal:  J Transl Med       Date:  2016-03-15       Impact factor: 5.531

10.  Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.

Authors:  Sigve Andersen; Elin Richardsen; Mehrdad Rakaee; Helena Bertilsson; Roy Bremnes; Magne Børset; Lill-Tove Busund; Tobias Slørdahl
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.